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IMPLICATIONS ANDPurpose: Acquisition of human papillomavirus (HPV) in women occurs predominantly through
vaginal sex. However, HPV has been detected in girls reporting no previous sex. We aimed to
determine incidence and risk factors for HPV acquisition in girls who report no previous sex in
Tanzania, a country with high HPV prevalence and cervical cancer incidence.
Methods: We followed 503 adolescent girls aged 15e16 years in Mwanza, Tanzania, with face-to-
face interviews and self-administered vaginal swabs every 3 months for 18 months; 397 girls
reported no sex before enrollment or during follow-up; of whom, 120 were randomly selected.
Samples from enrollment, 6-, 12-, and 18-month visits were tested for 37 HPV genotypes. Inci-
dence, clearance, point prevalence, and duration of any HPV and genotype-speciﬁc infections were
calculated and associated factors were evaluated.
Results: Of 120 girls who reported no previous sex, 119 were included, contributing 438 samples.
HPV was detected in 51 (11.6%) samples. The overall incidence of new HPV infections was 29.4/100
person-years (95% conﬁdence interval: 15.9e54.2). The point prevalence of vaccine types HPV-6,-
11,-16, and -18 was .9%, .9%, 2.0%, and 0%, respectively. Spending a night away from home and using
the Internet were associated with incident HPV, and reporting having seen a pornographic movie
was inversely associated with HPV incidence.
Conclusions: Incident HPV infections were detected frequently in adolescent girls who reported
no previous sex over 18 months. This is likely to reﬂect under-reporting of sex. A low-point
prevalence of HPV genotypes in licensed vaccines was seen, indicating that vaccination of these
girls might still be effective.
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the female and male anogenital tract [1]. The predominant
mechanism of HPV acquisition in women is thought to be
through penetrative vaginal sex since historically, HPV has only
been detected in a small proportion of girls and women who
report no previous sex [2,3], and HPV incidence and prevalence
have been shown to increase rapidly in women after reported
ﬁrst sex [4]. Risk factors for incident HPV infection, identiﬁed in
longitudinal data, include having a higher number of sex part-
ners [5,6]. In addition, HPV genotypes have been shown to be
concordant between couples in sexual relationships [7]. High-
risk (HR) HPV genotypes have been associated with cervical
cancer [8,9]. Vaccination against these HR HPV genotypes is
recommended before ﬁrst sex because the vaccine offers less
protection once an HPV genotype has been acquired [10].
Tanzania has one of the highest rates of cervical cancer in the
world and, to date, no national HPV vaccination program [11]. In
a previous cross-sectional analysis, we identiﬁed a high preva-
lence (8.4%) of HPV in girls who reported no previous sex [12].
HPV detection was associated with reporting having cleaned
inside the vagina, whichmay have been amarker for undisclosed
sexual activity [13]. To further investigate the detection of vaginal
HPV in girls who stated that they had not passed sexual debut,
we present results from longitudinal follow-up of these girls in
Mwanza, Tanzania. This study is the ﬁrst to report the incidence
of HPV in girls who report no previous sex in sub-Saharan Africa.
Methods
Study procedures
The cohort was enrolled between January and August 2012, as
described previously [12]. Brieﬂy, we enrolled eligible girls
attending government primary schools in three districts in the
Mwanza region of Tanzania that had been randomly selected in
preparation for an HPV vaccine trial [14]. Eligibility criteria
included having been in Class 6 in 2010 in one of the nonvaccine
schools, reporting never having previously had sex, being willing
to undergo study procedures, able to attend appointments, and
being 15 or 16 years old at the time of enrollment.
During the study, samples were collected every 3 months for
18 months as described previously [12]. At enrollment and each
follow-up visit, girls underwent a face-to-face interview in
Swahili using a structured questionnaire, which included ques-
tions on sexual behavior and intravaginal practices. Girls were
additionally asked to provide one self-administered vaginal swab
under the supervision of a trained research nurse. We present
data from a randomly selected subgroup of girls who reported
not having had sex during study follow-up.
Ethical considerations permissions
The Medical Research Coordinating Committee, Tanzania
(Ref: NIMR/HQ/R.8a/Vol. IX/1249) and the London School of
Hygiene and Tropical Medicine Ethics Committee (Ref: 6040)
approved the study protocol. Because participants were younger
than the age of legal consent, written informed consent was
required from a parent/guardian before written participant
assent. Girls with persistent HR HPV at study completion
(deﬁned as the same HR HPV genotype detected at two consec-
utive 6-month visits) were referred for follow-up with the Na-
tional Cervical Screening Program.Human papillomavirus detection and genotyping
Dry vaginal swabs were stored in cryotubes immediately after
collection and transported in cold boxes with ice packs before
submission to the Mwanza Intervention Trials Unit Laboratory in
Mwanza, where they were stored at 20C until they were
shipped to the Catalan Institute of Oncology in Barcelona. Sam-
ples from enrollment, month-6, -12, and -18 visits for girls
included in this substudy were tested using the Linear Array HPV
genotyping assay (Roche, CA) which detects 13 HR and 24 low-
risk (LR) genotypes [15]. We considered HPV genotypes catego-
rized by the International Agency for Research on Cancer as
associated with cancer (Group I) and probably associated with
cancer (Group IIa) as HR HPV genotypes [16]. All other genotypes
(Groups IIb: possibly associated with cancer and III: not associ-
ated with cancer) were considered LR types. Samples negative
for b-globin were considered inadequate for HPV genotyping.
Data management and statistical methods
Data were double entered into OpenClinica LLC (Akaza
Research, MA), and analysis was performed using Stata version
10.3 (StataCorp LP, TX).
Reported sexual behaviors were tabulated in all girls who
reported not having had sex and in those included in the present
study. Genotype-speciﬁc incidence was calculated using person-
time at risk from the date of enrollment. A new (incident)
infection was deﬁned as a ﬁrst positive test for the speciﬁc HPV
type among those not infected with that genotype at enrollment.
Date of infection was assumed to be midway between the last
negative and ﬁrst positive sample. Girls who had missed visits or
missing HPV results, which led to a gap in the observations, were
censored at the last available result before the gap.
Duration of infectionwas calculated from the date of infection
to the date of clearance (assumed to be midway between the last
positive and ﬁrst negative sample for that genotype). Clearance
of a genotype-speciﬁc infection was deﬁned as a single negative
sample for that genotype. Infections that were not cleared were
censored at the date of the last positive sample. If therewere two
positive samples with one intervening missing sample (e.g.,
positive at month-6 and -18 but with amissing sample at month-
12), duration was considered unknown and censored at the date
of the ﬁrst positive sample.
The overall incidence of all HPV infections was calculated as
the number of new infections (allowing multiple events at each
time point) over person-years at risk. Gaps (explained previously)
whereavisitwasmissedwere removed, but girlswereassumedat
risk again after a gap. The overall incidence rate was estimated
using Poisson regression with random effects to account for
clustering of infections within the same girl. The HPV genotypee
speciﬁc point prevalence was estimated as the number of visits
where the genotypewas detected, divided by the total number of
visits, including enrollment.
Poisson regression with random effects was used to estimate
rate ratios for factors associated with HPV incidence. A concep-
tual framework with three levels was used to build an adjusted
model; age was considered an a priori confounder. Age-adjusted
sociodemographic factors at enrollment were retained in a core
model if associated with HPV infection at p < .10. Time-varying
sociodemographic factors were added to this core model
sequentially and retained if associated at p < .10. Time-varying
behavioral factors were then added sequentially and retained if
Table 2
Incidence and point prevalence in adolescent girls who did not report sex at
enrollment or during 18 months follow-up
Outcome All girls (N ¼ 119)a Negative for all HPV
genotypes at enrollment
(HPV naïve; N ¼ 109)b
Incidence New infections/person-years (rate/100 person-years, 95% CI)c
All HPV 44/152.8 (29.4; 15.9e54.2) 40/140.6 (27.9; 14.7e53.0)
All HR HPV 18/152.8 (11.3; 5.8e22.1) 18/140.6 (12.4; 6.4e24.0)
All LR HPV 26/152.8 (18.1; 9.3e35.1) 22/140.6 (15.8; 7.9e31.7)
Prevalence Total infections (number of visits with at least one
infection/all visits; % of all visits)d
All HPV 87 (51/438; 11.6) 50 (24/402; 6.0)
All HR HPV 38 (29/438; 6.6) 23 (16/402; 4.0)
All LR HPV 49 (36/438; 8.2) 27 (17/402; 4.2)
CI ¼ conﬁdence interval; HPV ¼ human papillomavirus; HR ¼ high-risk;
LR ¼ low-risk.
a HPV incidence among all girls who did not report passing sexual debut
during the study includes 10 girls in whom prevalent HPV was detected at
enrollment.
b HPV incidence among girls who did not report passing sexual debut during
the study and no HPV was detected at enrollment.
c Rate estimated from random effects Poisson regression: point estimates and
95% CI take into account correlation of repeated events within girls. Girls
assumed to be continually at risk and can acquire more than one infection at each
visit.
d Total number of genotype-speciﬁc infections and number of visits where at
least one genotype was detected, at all visits including enrollment visit.
Table 1
Prevalence of reported behaviors among all girls in the study who did not report
sex at enrollment or during follow-up (n ¼ 396) and among those randomly
selected for the HPV incidence study (n ¼ 119)
Reported behavior Number of girls
reporting the
behavior among all
(n ¼ 396) who did
not report sexa (%)
Number of girls
reporting behavior
among (n ¼ 119)
who did not report
sexa and who have
HPV results (%)
At enrollment
Ever drank alcohol
Yes 1 (.3) 0 (0)
Ever smoked
Yes 0 (0) 0 (0)
Ever took drugs
Yes 0 (0) 0 (0)
Ever-cleansed vagina
Yes 68 (17.2) 20 (16.8)
Ever-kissed a boy
Yes 0 (0) 0 (0)
Boy ever touched breasts
Yes 22 (5.6) 8 (6.7)
Ever touched boy’s genitals or
boy touched girl’s genitals
Yes 2 (.5) 0 (0)
Ever had oral sex
Yes 0 (0) 0 (0)
During follow-upb
Spent a night away since
last visit
Yes 272 (68.7) 86 (72.3)
Used Internet everc
Yes 95 (24.0) 35 (29.4)
Ever watched a pornographic
moviec
Yes 62 (15.7) 17 (14.3)
Drank alcohol since last visit
Yes 4 (1.0) 1 (.8)
Practiced vaginal cleansing
since last visit
Yes 141 (35.6) 42 (35.3)
Kissed a boy since last visit
Yes 6 (1.5) 3 (2.5)
Boy touched breasts since
last visit
Yes 12 (3.0) 3 (2.5)
Touched boy’s genitals/boy
touched girl’s genitals
since last visit
Yes 2 (.5) 1 (.8)
a Girls who did not report sex at enrollment or during the study up to and
including the ﬁnal visit (18 months).
b Girls were asked at every visit whether they had experienced any of these
behaviors since they were last seen in the study.
c Girls were asked during follow-up if they had ever used the Internet or seen a
pornographic movie, but they were not asked when they had done that. After a
girl reported ever having used the Internet or having seen a pornographic movie,
all subsequent visits are counted as “yes.”
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assess the effects of variables at each level of the framework,
adjusted for more distal variables.Results
Study enrollment has been described previously [12]. Of 628
girls located, ageeligible, andconsented,504 (80%) reportednever
having had sex, and 481 were enrolled. Of those enrolled, 397
reported never having had sex during the study and conﬁrmedthis at the ﬁnal study visit. We randomly selected 120 (30.2%) of
thesegirls andexcludedonegirlwho spontaneously reported that
she had been HIV positive from birth (girls were not explicitly
asked this). Table 1 summarizes participant characteristics and
reported behaviors in all 396 girls in the cohort who reported no
previous sex and in the 119 girls included in this analysis.
At enrollment, 61 of the 119 (51.3%) girls were aged 16 years,
and the remainder was aged 15 years. Approximately half (52.9%)
lived in urban areas, 92.4% were Christian, 79.0% were in school,
and 19.3% were neither working nor in school. The ﬁnal study
visit was attended by 90.8% of girls. At this visit, 108 girls were
asked if they were circumcised (i.e., had experienced genital
cutting), and none reported this. Girls contributed 438 valid
specimens.
Overall, 10 of the 119 girls (8.5%) who never reported having
had sex had HPV detected at enrollment. The 119 girls contrib-
uted a total of 152.8 person-years (pys) of follow-up; during
which, 44 new HPV infections were detected. The overall inci-
dence of new HPV infections in girls who reported never having
had sex was 29.4 per 100 pys (95% conﬁdence interval [CI]:
15.9e54.2) and for new HR HPV infections was 11.3/100 pys (95%
CI: 5.8e22.1; Table 2). Infection with at least one HPV genotype
was detected at 11.6% of visits, and at least one HR HPV genotype
was detected at 6.6% of visits.
The HPV genotype with the highest incidence was HPV66
(2.7/100 pys), followed by HPV59 (2.6/100 pys), and HPV-16, -51,
-52, and -6 (2.0/100 pys for each; Table 3). The genotypes with
the highest point prevalence were HPV-16 (2.1%), HPV-42 (1.8%),
and HPV-61 (1.6%; Figure 1).
The mean duration of any new HPV infectionwas 7.0 months;
8.1 for anyHRHPV infection, and 6.6 for any LR infection (Table 3).
The rate of clearance of LR HPV infections was three times more
than that of HR HPV infections (103.3 vs. 28.8/100 pys).
In the adjusted analysis, there was strong evidence that
having spent a night away from home in the last 6 months
(adjusted risk ratio [aRR] ¼ 5.47; 95% CI ¼ 1.72e17.4) or having
Table 3
HPV genotype prevalence, incidence, duration, and clearance among 119 girls who did not report sex at enrollment or during up to 18 months follow-up
HPV type Prevalent HPV
infections (%)a
New infections/pys
(rate/100 pys)b
New infections that
were cleared (%)c
Number of new infections
cleared/pys (rate/100 pys)
Mean (median) months
duration (KaplaneMeier)d
HR genotypes
HPV-16 1 (1) 3/149.7 (2.0) 0 0/1.7 (0) 9.2e (f)
HPV-18 0 0/152.8 (0) d d d
HPV-31 0 1/152.6 (.7) 0 0/.3 (0) g
HPV-33 0 0/152.8 (0) d d d
HPV-35 1 (1) 0/151.4 (0) d d d
HPV-39 0 1/152.1 (.7) 0 0/.7 (0) g
HPV-45 0 0/152.8 (0) d d d
HPV-51 1 (1) 3/150.6 (2.0) 2 (67) 2/1.3 (159.0) 5.9 (5.8)
HPV-52 1 (1) 3/150.6 (2.0) 0 0/.8 (0) 3.2e (f)
HPV-56 1 (1) 1/152.1 (.7) 0 0/.3 (0) g
HPV-58 2 (2) 1/151.1 (.7) 0 0/.2 (0) g
HPV-59 1 (1) 4/151.3 (2.6) 0 0/1.0 (0) 3.1e (f)
HPV-68 0 1/152.2 (.7) 0 0/.7 (0) g
All HR infectionsh 8 18 2 (11) 2/6.9 (28.8) 8.1e (f)
LR genotypes
HPV-6 0 3/151.1 (2.0) 1 (33) 1/1.5 (67.3) 7.5e (6.0)
HPV-11 1 (1) 1/150.2 (.7) 1 (100) 1/.5 (194.3) g
HPV-26 0 2/151.4 (1.3) 1 (50) 1/.7 (135.0) 5.8 (5.8)
HPV-40 0 0/152.8 (0) d d d
HPV-42 2 (2) 1/150.1 (.7) 0 0/.3 (0) g
HPV-53 0 0/152.8 (0) d d d
HPV-54 0 0/152.8 (0) d d d
HPV-55 0 1/152.1 (.7) 0 0/.8 (0) g
HPV-61 1 (1) 2/150.4 (1.3) 1 (50) 1/.7 (136.5) 5.8 (5.8)
HPV-62 1 (1) 1/150.7 (.7) 1 (100) 1/.5 (207.5) g
HPV-64 0 2/151.9 (1.3) 1 (50) 1/.7 (137.6) 5.8 (5.8)
HPV-66 0 4/150.9 (2.7) 1 (25) 1/1.7 (58.0) 7.5e (5.8)
HPV-67 0 2/150.9 (1.3) 2 (100) 2/1.0 (207.5) 5.8 (5.8)
HPV-69 0 0/152.8 (0) d d d
HPV-70 0 1/152.6 (.7) 0 0/.3 (0) g
HPV-71 0 0/152.8 (0) d d d
HPV-72 0 0/152.8 (0) d d d
HPV-73 0 1/152.6 (.7) 0 0/.2 (0) g
HPV-81 1 (1) 0/151.4 (0) d d d
HPV-82 1 (1) 1/152.1 (.7) 0 0/.3 (0) g
HPV-83 0 0/152.8 (0) d d d
HPV-84 1 (1) 2/150.3 (1.3) 1 (50) 1/.7 (135.3) 6.0 (6.0)
HPV CP-108 0 1/152.6 (.7) 0 0/.2 (0) g
HPV IS-39 0 1/152.1 (.7) 1 (100) 1/.5 (208.1) g
All LR infectionsh 8 26 11 (42) 11/10.6 (103.3) 6.6e (5.8)
All HPV infections 16 44 13 (30) 13/17.6 (73.9) 7.0e (6.0)
Overall ﬁgures are highlighted in bold.
HPV ¼ human papillomavirus; HR ¼ high-risk; LR ¼ low-risk; pys ¼ person-years.
a Positive for that genotype at the enrollment visit.
b New infection deﬁned as ﬁrst positive test for the speciﬁc HPV type, among those not infected at enrollment.
c Clearance deﬁned as a negative sample for the speciﬁc genotype; denominator is total genotype-speciﬁc new infections.
d Mean duration of new infections estimated using KaplaneMeier methods restricted by the longest follow-up time (i.e., duration).
e Mean duration of infection for the genotype is underestimated because the individual with the longest observed duration was censored.
f Median duration could not be estimated because survival curve does not drop below 50%.
g One infection only, KaplaneMeier survival function not estimated.
h Total number of group (HR or LR)-speciﬁc infections among 119 girls.
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ciated with new HPV infection (Table 4). There was weak evi-
dence that having watched a pornographic movie was associated
with a lower risk of HPV acquisition (aRR ¼ .18; 95% CI ¼
.03e1.03) and that having cleansed inside the vaginawith soap in
the past 6 months, compared with not having cleansed was
associated with a new HPV infection (aRR ¼ 2.64; 95% CI ¼
.75e9.31).
Discussion
A total of 119 Tanzanian adolescent girls who reported never
having sex were followed for 18months. Tanzania has a very highHPV prevalence and one of the world’s highest incidences of
cervical cancer [11,17]. We found that 11% of the samples pro-
vided during the study period showed evidence of vaginal HPV
infection, which likely reﬂects under-reporting of sex or, less
likely, acquisition of HPV through nonpenetrative sex or vaginal
cleansing. Studies have compared self-reporting of sex with
biomarkers of recent sex [18], compared different methods of
interview [19,20], or carried out repeat surveys [21] in East
Africa, and have shown that under-reporting of sex is common.
Under-reporting may be particularly common in adolescent girls
in Tanzania since sex outside marriage or while schooling may
result in school expulsion, physical punishment, or legal repri-
mand for the male partner [22,23].
Figure 1. HPV-genotype point prevalence (95% CI) and number of infections at
all visits including enrollment among 119 girls who did not report sex at
enrollment or during 18-month follow-up. The HPV genotype-speciﬁc point
prevalence was estimated as the number of visits where the genotype was
detected, divided by the total number of visits attended including the enroll-
ment visit. Visits with missing vaginal samples, or with samples that were
b-globin negative, were excluded.
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or vaginal HPV was detected in 0%e1.5% of self-reported virgins
in Europe, Australia, and United States of America [2,3,24,25].
Longitudinal studies, which sampled girls who consistently re-
ported no previous sex at multiple time points, have detected
higher rates of HPV. One study in girls in the United States of
America, median age of 19 years, detected HPV in 7.8% of girls
who were followed for 24 months and consistently reported that
they had never had sex [4]. Another study in the United States of
America followed 14- to 17-year-old girls every 3 months for a
median of 5.2 years and found HPV in 10 of 22 (45.5%) who re-
ported never having had sex [26]. Both studies identiﬁed an as-
sociation between nonpenetrative sexual behaviors and HPV
detection in girls. Nonpenetrative sex practices including
handegenital contact and oralegenital sex have been identiﬁed
as risk factors for HPV acquisition in heterosexual women [4,27]
and in homosexual womenwho report never having had penilee
vaginal sex [28]. In our study population, oralegenital sex isinfrequently reported in adolescents [22,29] and was not re-
ported by any of our participants. Handegenital contact was
reported by only two participants.
Intravaginal cleansing was associated with prevalent HPV in
girls who reported never having had sex at the time of cohort
enrollment [12]. We have suggested that intravaginal cleansing
was most likely to have been a marker for unreported sex
but additionally commented that the practice of intravaginal
cleansing, which involves inserting ﬁngers or a cloth inside the
vagina, may introduce HPV from external genitalia or fomites. In
this current longitudinal study, there was no strong evidence
that recent intravaginal cleansing was associated with new HPV
infection. This may be due to the more robust analysis offered by
longitudinal data compared with cross-sectional data. A further
possible explanation may be the small number of girls (n ¼ 6)
who at enrollment reported no previous sex but corrected this
during follow-up; these girls were included in the cross-sectional
analysis [12] but excluded from this study. There was weak evi-
dence of an association with reported cleansing with soap
compared with not cleansing in the past 6 months. Again, this is
most likely to be amarker of unreported sex because girls may be
more likely to perform intravaginal cleansing if they believe that
this practice is appropriate or desirable before or after sex or that
it is effective in reducing the risk of STI or pregnancy [13]. HPV
has been detected on ﬁngers of women with genital warts, on
toilet seats in airports, and on surfaces in sexual health clinics in
the United Kingdom [30e32], and therefore self-infection, via
ﬁngers or fomites (e.g., cloths), remains a theoretical possibility.
We also observed a strong association between spending a
night away from home in the past 6 months and HPV acquisition.
Traveling or short-time migration has been associated with HIV
infection in previous studies in sub-Saharan Africa [33,34], but
notwith HPV. It is likely that spending a night away fromhome is
a marker for unreported sex and therefore HPV risk.
One of the limitations of this study was that we only tested
samples from girls every 6 months. Therefore, it is likely that
HPV-incidence was underestimated because some short-lived
infections may have cleared quickly between visits. This may
have been partially mitigated by using the highly sensitive HPV
Roche Linear Array, reducing the risk of false-negative tests. A
further limitation of the study is the relatively small number of
events in the risk factor analysis, which resulted in large standard
errors and reduced power to detect associations, and made it
difﬁcult to adequately adjust for all potential confounders. The
major strength of this study was the face-to-face interviews.
These included current colloquial terms for sexual behaviors. The
interviewers were experienced in sexual behavior research with
adolescents and attempted to meet the same participant at every
visit, establishing a trusting relationship and potentially redu-
cing under-reporting. A nested study of alternative interview
methods found no increase in reporting of sex. Unfortunately,
interviews did not include questions about masturbation, which
has previously been reported by adolescent girls in Tanzania [29]
and which could potentially lead to transmission via ﬁngers.
Similarly, HPV could be acquired through fomite transmission
during female genital cutting via unsterilized equipment or the
ﬁngers of the practitioner. Although only one participant in our
cohort reported having undergone genital cutting, this may have
been an underestimate: a study of 15- to 44-year-old women in
Tanzania found 73% had evidence of genital cutting [35]. Finally,
this cohort were selected based on reporting never having
had sex and were recruited from school registers, potentially
Table 4
Factors associated with any new HPV infection among 119 girls who did not report sex at enrollment or during 18 months follow-up
Variable Number of infections/person-years
(rate/100 pys)
Crude RR (95% CI) Adjusted RR (95% CI)a
Sociodemographic at enrollment
Age at enrollment p ¼ .40
15 years 29/73.9 (36.9) 1
16 years 15/78.9 (21.7) .59 (.17e1.99)
Religion p ¼ .78 p ¼ .85
Christian 37/141.5 (27.2) 1 1
Muslim 5/8.9 (50.0) 1.84 (.17e19.81) 1.70 (.16e18.03)
Other 2/2.4 (69.9) 2.57 (.04e176.6) 2.08 (.03e137.8)
SES score (tertiles)b p ¼ .56 p ¼ .76
Low 9/47.1 (19.3) 1 1
Middle 12/52.4 (25.0) 1.30 (.27e6.13) 1.21 (.24e6.02)
High 23/53.4 (42.4) 2.20 (.49e9.81) 1.89 (.32e11.12)
Sociodemographic (time varying)
Current residence p ¼ .07 p ¼ .09
Urban 34/84.7 (40.3) 1 1
Rural 10/68.1 (15.9) .39 (.14e1.10) .41 (.15e1.16)
Current occupation P ¼ .24 p ¼ .24
School 28/117.5 (27.2) .27 (.02e2.89) .30 (.03e3.05)
Work/vocational training 1/7.8 (7.2) 1 1
Not working 15/27.6 (43.9) 1.61 (.65e4.02) 1.69 (.68e4.24)
Spent a night away since last seen p < .001 p < .001
No 26/112.0 (20.0) 1 1
Yes 18/40.8 (109.6) 5.47 (1.72e17.4) 5.63 (1.81e17.49)
Behavioral (time varying)
Current menstrual hygiene p ¼ .12 p ¼ .18
Cloth 10/58.6 (22.5) 1 1
Underwear 8/21.6 (21.8) .97 (.23e4.10) .72 (.15e3.56)
Sanitary pad 26/60.3 (45.3) 2.02 (.55e7.34) 1.31 (.30e5.76)
Premenarche 0/12.4 (.0) d d
Used Internetc p ¼ .12 p ¼ .05
No 34/132.7 (25.9) 1 1
Yes 10/20.1 (58.0) 2.24 (.79e6.36) 3.08 (.94e10.13)
Watched a pornographic moviec p ¼ .20 p ¼ .05
No 42/137.9 (31.6) 1 1
Yes 2/15.0 (11.5) .36 (.07e1.92) .22 (.04e1.24)
Cleansed vagina in last 6 monthsd p ¼ .03 p ¼ .08
No 24/118.4 (21.2) 1 1
Yes 20/34.4 (59.2) 2.79 (1.08e7.17) 2.43 (.87e6.76)
Substance used for vaginal cleansing p ¼ .01 p < .001
Did not cleanse 30/126.8 (25.5) 1 1
Soap or soap and water 14/19.1 (103.4) 4.05 (1.30e12.63) 3.01 (.86e10.59)
Water only 0/6.9 (.0) d d
Kissed a boy in the last 6 months p ¼ .56 p ¼ .36
No 43/151.4 (28.6) 1 1
Yes 1/1.5 (87.1) 3.05 (.06e155.9) 5.88 (.09e390.8)
Boy touched participant’s breasts in last 6 months
No 44/151.9 (29.6) d d
Yes 0/1.0 (.0) d d
Boy touched participant’s genitals or participant touched
boy’s genitals in the last 6 months
No 44/152.4 (29.4) d d
Yes 0/.5 (.0) d d
CI ¼ conﬁdence interval; pys ¼ person-years; RR ¼ relative risk.
a Sociodemographic factors at enrollment adjusted for age (a priori). Time-varying sociodemographic factors adjusted for age (a priori); no other baseline socio-
demographic factors were associated with HPV infection. Time-varying behavioral factors adjusted for age (a priori) and all independent sociodemographic factors:
spending a night away.
b Socioeconomic status (SES) was determined using an asset index created by combining data collected from the entire cohort at enrollment on household ownership
of the following items: radio, phone, car, motorbike, bicycle, livestock, television, or land. Principal components analysis techniques were used.
c Girls were asked during follow-up if they had ever used the Internet or seen a pornographic movie, but they were not asked when they had done that. After a girl
reported ever having used the Internet or having seen a pornographic movie, all subsequent visits are counted as “yes.”
d Vaginal cleansing is cleaning inside the vagina with water, soap, or other products using ﬁngers or a cloth.
C.F. Houlihan et al. / Journal of Adolescent Health 58 (2016) 295e301300affecting representativeness. However, attendance at primary
school is a legal requirement, and most children are likely to at
least be registered in primary school. Furthermore, of those
located and age eligible, 80% reported never having had sex,
indicating that the cohort is likely to be representative of most
girls of the same age who are enrolled in schools in Tanzania.Our results demonstrate that some Tanzanian adolescent girls
who report never having had sex have a relatively high incidence
of vaginal HPV. HPV-16 and -18 are responsible for >70% of
cervical cancers, and currently available HPV vaccines offer a
high level of protection from these genotypes [36,37]. In our
study, HPV-16 was the most frequently detected genotype.
C.F. Houlihan et al. / Journal of Adolescent Health 58 (2016) 295e301 301However, 98% of these girls had no evidence of HPV-16 or -18,
suggesting that catch-up vaccination campaigns in girls older
than the current target population recommended by WHO
(9e13 years old [38]) may be effective at reducing cervical can-
cer. This may be particularly relevant because the Tanzania
vaccination program has proposed primarily targeting girls in
Year 4 if they are in school or 9-year-old girls if out of school.
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